The investigation was completed by conducting a thorough evaluation of the product and the reported information.The issue was determined to be a defect in the product.The administration instructions could contain information on frequency, fractional dosage, infusion rate, holding orders, etc.And could result in serious injury if a drug is administered incorrectly.The pharmacist should check the ordering dose and the administration instructions.If a dose reduction had been made and the administration instructions did not change, this should be investigated before the order is approved.Reducing the dose and editing the administration instructions would be a common workflow, and the error is easily detectable through normal clinical checks.No patients were mistreated.The defect will be fixed in a future release.
|